×

Corvus Pharmaceuticals to Present at AACR Annual Meeting April 16 – 20 in New Orleans

BURLINGAME, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs at the American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016 in New Orleans.

Following are the specifics for Corvus’ two poster presentations:

  • Inhibition of Adenosine A2A Receptor (A2AR) by CPI-444 Enhances CD8+ T cell Killing of a HER-2/neu Expressing Murine Tumor

Authored by Blake A. Scott1, Todd Armstrong2, Elizabeth M. Jaffee2
Affiliations: 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore
Session Category: Experimental and Molecular Therapeutics
Session Date/ Time: Sunday, Apr 17, 1:00 PM – 5:00 PM
Location: Morial Convention Center, Halls G-J, Poster Section 17, Poster Board 1

  • The Adenosine A2A Receptor Antagonist, CPI-444, Blocks Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Alone and In Combination with Anti-PD-1 and Anti-PD-L1

Authored by Stephen Willingham1, Po Y. Ho1, Robert Leone2, Emily Piccione1, Carmen Choy1, Andrew Hotson1, Joseph Buggy1, Jonathan Powell2, Richard Miller1
Affiliations: 1Corvus Pharmaceuticals, Burlingame, Calif.; 2Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore
Session Category: Immunology
Session Date/ Time: Monday, Apr 18, 1:00 PM – 5:00 PM
Location: Morial Convention Center, Halls G-J, Poster Section 26, Poster Board 21

The following oral presentation will take place as follows:

  • Adenosine A2a Receptor (A2aR) Antagonist as a Means of Enhancing the Efficacy of Checkpoint Blockade and Adoptive T Cell Therapy

Authored by Robert D. Leone, Judson M. Englert, Chih-Hsien Cheng, Jiayu Wen, Min-Hee Oh, Im-Hong Sun, Chirag Patel, Ian A. Bettencourt, Jonathan D. Powell
Affiliation: Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins University School of Medicine, Baltimore
Session Category: Immunology
Session Date/ Time: Tuesday, Apr 19, 4:20 PM – 4:35 PM
Location: Morial Convention Center, New Orleans Theater C

To learn more about the Corvus pipeline visit http://www.corvuspharma.com/technology/.

ABOUT CORVUS PHARMACEUTICALS
Corvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT: Leiv Lea Chief Financial Officer LLea@corvuspharma.com 650-900-4522 MEDIA CONTACT: Julie Normart, W2O Group 415-946-1087 jnormart@w2ogroup.com

Source:Corvus Pharmaceuticals